Isolated left lung perfusion with melphalan and human tumor necrosis factor-α for pulmonary metastatic adenocarcinoma in the WAG/Rij rat was studied.Methods.
Survival was determined for melphalan, human tumor necrosis-α. Lung, pulmonary effluent, and serum melphalan were analyzed by chromatography after isolated lung perfusion or intravenous injection. On day 0, rats were injected with 2.0 × 106 CC531S cells intravenously. On day 7, rats underwent sham thoracotomy, received melphalan intravenously, or underwent isolated left lung perfusion with saline, melphalan, tumor necrosis factor, and a combination of the latter two. On day 14, tumor nodules were counted.Results.
For the doses of 400 μg tumor necrosis factor, 1,000 μg tumor necrosis factor, or both melphalan and tumor necrosis factor (2 mg + 200 μg), survival rates after contralateral pneumonectomy were 33%, 17%, and 80%, respectively. Survival in all other groups was 100%. Left lung melphalan level was significantly higher after isolated lung perfusion compared to intravenous administration. Significantly fewer left lung nodules were found for 0.5 mg isolated lung perfusion with melphalan (28 ± 17) compared to isolated administration (200 ± 0) (p = 0.001), and for 1.0 mg intravenous lung perfusion with melphalan (16 ± 10) compared to controls (171 ± 65) (p = 0.00047). Tumor necrosis factor showed no significant effect.Conclusions.
Isolated lung perfusion with melphalan is an effective treatment for pulmonary metastases from adenocarcinoma in the rat.